Mr. Stephen Kilmer reports

INTELGENX ANNUNCES CHANGES TO ITS BOARD OF DIRECTORS

Frank Stegert and Srinivas Rao have resigned from the board of directors of IntelGenx Technologies Corp. effective Dec. 2, 2023.

Mr. Stegert and Dr. Rao were the board designees for atai Life Sciences AG (atai) pursuant to the purchaser rights agreement by and between the company and atai.

On Dec. 2, 2023, the board appointed Sahil Kirpekar, MD, and Ryan Barrett as the new atai board designees pursuant to the rights agreement, to serve until the 2024 annual meeting of the company's stockholders, or until their respective successors are duly elected and qualified.

Dr. Kirpekar has served as atai's chief business officer since 2022 and Mr. Barrett has served as atai's senior vice-president and general counsel since August, 2020.

About IntelGenx Technologies Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including Versafilm, Disinteq, Vetafilm and transdermal Vevaderm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development, analytical method development, clinical monitoring, intellectual property, and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

We seek Safe Harbor.